Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

VTT Searches for Novel Biomarkers and Targets for Treating Type 2 Diabetes

Published: Thursday, August 23, 2012
Last Updated: Thursday, August 23, 2012
Bookmark and Share
Research focus on dysfunction of cells and effect of change in lifestyle.

VTT is participating in two new European projects focusing on type 2 diabetes. The projects aim at identifying new therapeutic choices and strategies for preventing the disease.

Focus is on obtaining information on cellular dysfunction in diabetes and the effects of changes in lifestyle.

The goal includes planning individual lifestyle instructions for people at high risk of diabetes and exploiting the results in a major European health insurance system.

The EU BetaBAT project aims at developing individual therapeutic choices for type 2 diabetics by identifying the connection between the genome and individual cell-level changes causing the disease.

The scientists will use systems biological tools to boost the capacity of beta cells and brown adipocytes for regaining homeostatic control.

The other EU project, DEXLIFE, aims at disease prevention by identifying novel diagnostic and predictive biomarkers to detect the progression toward type 2 diabetes in individuals at high risk of the disease.

Large-scale data will be acquired during the project, including information on genes and metabolites.

The intervention aiming at type 2 diabetes prevention will be set up in the real-life context of a major European health insurance system.

In both projects VTT leads the work packages on integration and modelling of data.

VTT has a central role in applying systems biology strategies - including metabolomics, integrative bioinformatics and biosystems modelling - to identify putative organelle-specific targets (BetaBAT) and early predictive markers of type 2 diabetes progression (DEXLIFE).

The global prevalence of diabetes has reached 285 million and is projected to rise to 435 million by 2030. Type 2 diabetes is preventable by sustained changes in diet and physical exercise.

Despite this, modern societies are already approaching 10% population prevalence of diabetes, and another 15% with pre-diabetes. The costs of type 2 diabetes are huge, approaching 10% of all health costs.

The EU projects are funded by the FP7-Health-2010 Seventh Framework programme.

BetaBAT and DEXLIFE are 4-year collaborative projects with partners from around Europe and United States. VTT’s total budget in the two projects is 1.91 million Euros.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos